Company profile · Biotech & medical
GlycoNex In
台灣醣聯生技醫藥股份有限公司 · 4168
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
GlycoNex develops antibody-drug conjugates, pro-antibodies, and biosimilars.[1]
Anti-glycan antibodies anchor a pipeline of antibody-drug conjugates, pro-antibody ADCs, and bispecific ADCs, alongside biosimilar programs such as SPD8 and SSR.[1]
The company provides contract development and manufacturing for external partners.[2]
Based in Taipei, GlycoNex is a clinical-stage biotech and a biopharmaceutical company focused on antibody-based therapeutics.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$12m | – | – |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$1m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | GlycoNex Incorporation |
|---|---|
| Chinese name | 台灣醣聯生技醫藥股份有限公司 |
| Stock code | 4168 (TPEx) |
| Industry | Biotech & medical |
| Founded | 01 Feb 2001 |
| Listed | 18 Dec 2012 |
| Paid-in capital | NT$1.1bn |
| Chairman | 張東玄 |
| President | 楊玫君 |
| Headquarters | 8F., No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 22175,Taiwan |
| Website | http://www.glyconex.com.tw/ |
| Official business description | 抗癌用之單株抗體開發 · 單株抗體標的授權 · 醣質抗原與蛋白質藥物相關委託服務 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- About GlycoNex — Glycobiology, Pipeline, and People | GlycoNex · website · retrieved 04 Nov 2026
- GlycoNex, Inc. — Glycan-Directed Cancer Immunotherapy | 台灣醣聯 · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list